Citations 0
June 2, 1999

Adding Behavioral Therapy to Medication for Smoking Cessation

Author Affiliations

Margaret A.WinkerMD, Deputy EditorIndividualAuthorPhil B.FontanarosaMD, Interim CoeditorIndividualAuthor


Copyright 1999 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.1999

JAMA. 1999;281(21):1983-1985. doi:10-1001/pubs.JAMA-ISSN-0098-7484-281-21-jbk0602

To the Editor: The increasing market of smoking cessation pharmacotherapies underscores the great need for these prescription and over-the-counter products for this worldwide health problem. It is important to discuss another area of pharmacotherapy for smoking cessation that was not discussed in the article by Dr Hughes and colleagues.1

Rose and colleagues2 have demonstrated the therapeutic utility of combining the nicotine antagonist mecamylamine with nicotine for the treatment of smoking cessation. These investigators demonstrated that mecamylamine given orally with nicotine patches significantly prolonged the duration of continuous smoking abstinence.2 Furthermore, this combination reduced ad-lib smoking, smoking satisfaction, and cigarette craving. These studies have promoted the development of the mecamylamine nicotine patch currently in phase 3 clinical trials. However, it is now possible to use oral mecamylamine and nicotine patches as was done in the study by Rose et al.

First Page Preview View Large
First page PDF preview
First page PDF preview